MétaCan
Menu
← Back to cohort

Abstract S2-01: Theranostic multiparametric tests improve residual risk assessment in early luminal breast cancer

2015· article· en· W1504632404 on OpenAlexaff
John M.S. Bartlett, Vicky S. Sabine, Syed Haider, Camilla Drake, Cheryl Crozier, Cindy Q. Yao, Cassandra Brookes, Cornelis JH van de Velde, Annette Hasenburg, D. G. Kieback, Christos Markopoulos, Luc Dirix, Caroline Seynaeve, Daniel Rea, Paul C. Boutros

Bibliographic record

VenueCancer Research · 2015
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicBreast Cancer Treatment Studies
Canadian institutionsOntario Institute for Cancer ResearchUniversity of Toronto
Fundersnot available
KeywordsGene signatureBreast cancerOncologyExemestaneMedicineInternal medicineCohortGene expressionGene expression profilingCancer researchCancerBioinformaticsBiologyGeneTamoxifenGenetics

Abstract

fetched live from OpenAlex

Abstract Background: Despite rapidly expanding availability of multiparametric tests which inform residual risk following adjuvant therapy for early breast cancer current approaches provide minimal information on the appropriate targeted therapy to be selected for patients at high risk of recurrence. We hypothesised that inclusion of key signalling nodes from driver molecular pathways in early breast cancer in residual risk signatures would both improve risk stratification and identify candidate theranostic targets for the next generation of clinical trials. Methods: RNA was extracted from FFPE luminal breast cancers from the TEAM pathology study (Exemestane versus Tamoxifen-Exemestane). Gene expression analyses were performed for 29 genes mapped across key signalling nodes within the PIK3CA pathway. mRNA assessment for IHC4 (ER, PgR, HER2 and Ki67) was included in the model. Quantitative gene expression was performed using the Nanostring platform. Novel signatures were trained in a randomly selected sub-set of the TEAM pathology cohort (n=˜1700) and validated using the remaining 50% of patients (n=˜1700). Results presented represent those from the validation cohort. Results: The IHC4-protein and IHC4-mRNA risk scores were highly correlated (Rho=0.72, p=4.12x10-265), suggesting the mRNA abundance-based classifier is able to serve as a good substitute for the protein-based model. A gene signature including IHC4 markers assessed by mRNA performed significantly better (AUC 0.70 vs 0.66) than conventional IHC4. A gene signature including 4 signalling modules from the PIK3CA pathway significantly outperformed both IHC4 and the 4 gene (ER, PgR, HER2, Ki67) classifier (AUC 0.75; p = 3.23x10-7 vs IHC4 and 1.39x10-3 vs "IHC4mRNA"). Conclusions: Inclusion of PIK3CA signalling modules identified key genes/nodes which are linked to early relapse in luminal breast cancer and provided a significantly improvement in risk classification when compared to a currently validated multiparameter test. Citation Format: John MS Bartlett, Vicky S Sabine, Syed Haider, Camilla Drake, Cheryl Crozier, Cindy Q Yao, Cassandra L Brookes, Cornelis JH van de Velde, Annette Hasenburg, Dirk G Kieback, Christos Markopoulos, Luc Y Dirix, Caroline Seynaeve, Daniel W Rea, Paul C Boutros. Theranostic multiparametric tests improve residual risk assessment in early luminal breast cancer [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr S2-01.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.004
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.004
Threshold uncertainty score0.012

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.004
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.001
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0040.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.057
GPT teacher head0.413
Teacher spread0.356 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2015
Admission routes1
Has abstractyes

Explore more

Same venueCancer Research→Same topicBreast Cancer Treatment Studies→French-language works237,207→